









Markets
/
Stocks
/
nasdaq-vir
/

Vir Biotechnology Inc

VIR

7.190USD

+0.270+3.90%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

999.57MMarket Cap

LossP/E TTM



Vir Biotechnology Inc

7.190

+0.270+3.90%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vir Biotechnology Inc

Currency: USD Updated: 2026-02-06

Key Insights

Vir Biotechnology Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 71 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.88.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vir Biotechnology Inc's Score

Industry at a Glance

Industry Ranking

71 / 392

Overall Ranking

191 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Vir Biotechnology Inc Highlights

StrengthsRisks

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 74.20M.

Fairly Valued

The company’s latest PE is -1.99, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 108.65M shares, decreasing 10.85% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 37.42K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

15.875

Target Price

+129.41%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Vir Biotechnology Inc is 5.88, ranking 313 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 240.00K, representing a year-over-year decrease of 89.92%, while its net profit experienced a year-over-year decrease of 23.66%.

Score

Industry at a Glance

Previous score

5.88

Change



Financials

6.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Vir Biotechnology Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Vir Biotechnology Inc is 8.33, ranking 50 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.99, which is -499.31% below the recent high of 7.93 and -1158.71% above the recent low of -25.00.

Score

Industry at a Glance

Previous score

8.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Vir Biotechnology Inc is 8.40, ranking 124 out of 392 in the Biotechnology & Medical Research industry. The average price target is 15.00, with a high of 31.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

15.875

Target Price

+111.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Vir Biotechnology Inc

VIR

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Vir Biotechnology Inc is 7.18, ranking 95 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.21 and the support level at 5.93, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.02

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.058

Neutral

RSI(14)

53.917

Neutral

STOCH(KDJ)(9,3,3)

32.035

Sell

ATR(14)

0.523

High Vlolatility

CCI(14)

-20.367

Neutral

Williams %R

35.833

Buy

TRIX(12,20)

0.944

Sell

StochRSI(14)

27.109

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.400

Sell

MA10

7.493

Sell

MA20

7.000

Buy

MA50

6.528

Buy

MA100

6.086

Buy

MA200

5.628

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Vir Biotechnology Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.10%, representing a quarter-over-quarter decrease of 3.92%. The largest institutional shareholder is The Vanguard, holding a total of 12.53M shares, representing 9.00% of shares outstanding, with 2.65% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

SB Investment Advisers (UK) Limited

14.27M

-1.33%

BlackRock Institutional Trust Company, N.A.

13.72M

-0.93%

ARCH Venture Partners

12.92M

The Vanguard Group, Inc.

Star Investors

12.78M

-3.24%

GSK plc

8.55M

State Street Investment Management (US)

5.24M

-0.26%

Scangos (George A)

3.78M

-12.72%

Dimensional Fund Advisors, L.P.

2.98M

-0.97%

OrbiMed Advisors, LLC

2.38M

Geode Capital Management, L.L.C.

2.25M

-0.28%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Vir Biotechnology Inc is 4.70, ranking 73 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.70. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.